MaltSci 麦伴科研

Appearance

Popular Reports / Genomics

This report is written by MaltSci based on the latest literature and research findings

How does CRISPR-Cas9 target specific genes? ​

Abstract ​

The CRISPR-Cas9 system has revolutionized genetics by enabling precise and efficient gene editing, with roots in bacterial immune responses. This technology utilizes a guide RNA (gRNA) to direct the Cas9 nuclease to specific DNA sequences, facilitating targeted modifications. The effectiveness of CRISPR-Cas9 relies on the design of gRNAs that complement target DNA sequences, requiring a protospacer adjacent motif (PAM) for Cas9 binding. While the system offers remarkable potential for applications in agriculture and gene therapy, challenges such as off-target effects must be addressed to enhance specificity and safety. Recent advancements include engineered Cas variants and novel editing techniques that improve targeting precision. Additionally, ongoing research into off-target effects and methods to minimize unintended modifications is critical. Ethical considerations surrounding CRISPR applications, particularly in human gene editing, highlight the need for robust regulatory frameworks and public engagement. This review synthesizes current knowledge on CRISPR-Cas9 mechanisms and implications, emphasizing the importance of continued exploration in this rapidly evolving field to unlock its full potential for biomedical research and therapeutic applications.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of the CRISPR-Cas9 System
    • 2.1 Historical Context and Discovery
    • 2.2 Components of CRISPR-Cas9: Cas9 and gRNA
  • 3 Mechanism of Gene Targeting
    • 3.1 gRNA Design and Target Recognition
    • 3.2 Role of PAM (Protospacer Adjacent Motif) in Targeting
  • 4 Off-Target Effects and Specificity Challenges
    • 4.1 Factors Contributing to Off-Target Effects
    • 4.2 Methods to Assess and Minimize Off-Target Activity
  • 5 Innovations and Future Directions
    • 5.1 Enhanced Specificity: New Cas Variants
    • 5.2 Applications in Gene Therapy and Beyond
  • 6 Ethical Considerations in CRISPR Applications
    • 6.1 Ethical Implications of Gene Editing in Humans
    • 6.2 Regulatory Framework and Public Perception
  • 7 Conclusion

1 Introduction ​

The CRISPR-Cas9 system has emerged as a groundbreaking tool in the field of genetics, revolutionizing the way researchers manipulate DNA. Originating from a bacterial adaptive immune response, this technology enables precise and efficient modifications to the genomes of various organisms, including plants, animals, and humans. The ability to edit genes with unprecedented accuracy has significant implications for biomedical research, agriculture, and therapeutic applications. Understanding the mechanisms by which CRISPR-Cas9 targets specific genes is crucial for optimizing its use in research and clinical settings.

The significance of CRISPR-Cas9 technology lies in its potential to address a myriad of genetic disorders and improve agricultural productivity. By enabling targeted gene editing, CRISPR-Cas9 facilitates the development of genetically modified organisms that can withstand diseases, pests, and environmental stressors, thereby enhancing food security [1]. In the biomedical realm, CRISPR-Cas9 has opened new avenues for gene therapy, allowing for the correction of mutations that cause various diseases, including cancer and neurodegenerative disorders [2][3]. The ability to design specific guide RNAs (gRNAs) that direct the Cas9 nuclease to precise locations in the genome is central to this technology, making it a powerful tool for both functional genomics and therapeutic interventions [4].

Currently, research into the CRISPR-Cas9 system is rapidly advancing, with numerous studies exploring its components, mechanisms, and applications. The foundational understanding of CRISPR-Cas9 includes its two main components: the Cas9 nuclease, which introduces double-strand breaks in the DNA, and the gRNA, which guides Cas9 to its target [5]. The design of gRNAs is pivotal for ensuring specificity, as they must complement the target DNA sequence while also recognizing the protospacer adjacent motif (PAM), a short DNA sequence required for Cas9 binding [6]. Furthermore, the challenges associated with off-target effects—unintended modifications to non-targeted regions of the genome—have prompted ongoing research aimed at enhancing the specificity and safety of CRISPR-Cas9 applications [4][7].

This review will systematically explore the mechanisms by which CRISPR-Cas9 targets specific genes. We will begin with an overview of the CRISPR-Cas9 system, including its historical context and the components involved in gene editing. Next, we will delve into the mechanism of gene targeting, focusing on gRNA design and the role of PAM in target recognition. We will then discuss the challenges posed by off-target effects and the factors contributing to these issues, along with methods to assess and minimize off-target activity. Innovations in CRISPR technology that enhance precision and reduce unintended consequences will also be highlighted, alongside ethical considerations surrounding gene editing in humans. Finally, we will conclude with a discussion of future directions for CRISPR-Cas9 applications in biomedical research and therapy, emphasizing the importance of continued exploration in this rapidly evolving field.

By synthesizing current knowledge and ongoing research, this review aims to provide a comprehensive understanding of how CRISPR-Cas9 targets specific genes and the implications of this technology for future applications in various domains. Understanding these mechanisms is essential for harnessing the full potential of CRISPR-Cas9 in both research and therapeutic contexts, paving the way for advancements in genetic engineering and precision medicine.

2 Overview of the CRISPR-Cas9 System ​

2.1 Historical Context and Discovery ​

CRISPR-Cas9 is a groundbreaking genome-editing technology that allows for the precise targeting and modification of specific genes within an organism's genome. The system is derived from the adaptive immune response of certain bacteria, which utilize CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) sequences and associated proteins (Cas) to defend against viral infections. The CRISPR-Cas9 system, particularly, employs a guide RNA (gRNA) that directs the Cas9 nuclease to specific DNA sequences, enabling targeted modifications.

The mechanism of CRISPR-Cas9 involves several critical steps. Initially, the gRNA, which is designed to be complementary to a specific target DNA sequence, binds to the Cas9 protein. This gRNA-Cas9 complex then scans the genome for a matching sequence. Upon locating the target site, the Cas9 protein introduces a double-strand break (DSB) in the DNA at the specified location. This break activates the cell's natural DNA repair mechanisms, which can be harnessed to introduce specific genetic changes, such as insertions, deletions, or replacements, through various repair pathways, including non-homologous end joining (NHEJ) or homology-directed repair (HDR) [4].

Historically, the CRISPR-Cas9 system was discovered as part of the bacterial immune system, with its potential for genome editing being realized around 2012. Since then, it has been rapidly adopted across various fields of biological research, including agriculture, medicine, and basic biological studies. Its simplicity and efficiency have made it a versatile tool for researchers, enabling the generation of genetically modified organisms for the study of gene function and disease mechanisms [8].

The specificity of CRISPR-Cas9 is largely determined by the design of the gRNA, which must be complementary to the target DNA sequence, typically requiring a protospacer adjacent motif (PAM) sequence for Cas9 binding. Variations in the gRNA sequence can be made to target different genes, making CRISPR-Cas9 a highly adaptable system. However, challenges such as off-target effects—where the Cas9 may inadvertently cut at unintended sites—have led to ongoing research aimed at enhancing the specificity and safety of the system. Modifications to the gRNA or the Cas9 enzyme itself have been explored to reduce these off-target activities and improve the overall precision of genome editing [9].

In summary, the CRISPR-Cas9 system operates through a well-defined mechanism of RNA-guided DNA targeting, which has evolved from its origins in bacterial immunity to become a revolutionary tool in modern genetic engineering. Its ability to target specific genes with high precision has opened new avenues for research and therapeutic applications, although challenges regarding specificity and delivery remain active areas of investigation [3][5].

2.2 Components of CRISPR-Cas9: Cas9 and gRNA ​

The CRISPR-Cas9 system is a revolutionary tool for genome editing, widely recognized for its precision and versatility in targeting specific genes across various organisms. The system consists of two primary components: the Cas9 protein and the guide RNA (gRNA).

The Cas9 protein is an RNA-guided endonuclease that plays a crucial role in the genome editing process. It functions as a molecular "scissors" that can introduce double-strand breaks in the DNA at specific locations. This specificity is determined by the sequence of the gRNA, which directs Cas9 to the target DNA sequence. The gRNA is designed to be complementary to a specific region of the target gene, ensuring that Cas9 binds to the correct location within the genome.

The gRNA itself is a short synthetic RNA that contains two essential parts: a sequence that is complementary to the target DNA and a scaffold region that binds to Cas9. The design of the gRNA is critical for the success of the CRISPR-Cas9 system, as it determines the specificity of the Cas9 nuclease. The target DNA sequence must be adjacent to a protospacer adjacent motif (PAM), a short sequence that is recognized by Cas9, which is essential for the binding and cleavage of the target DNA. The typical PAM sequence for the most commonly used Cas9 from Streptococcus pyogenes is "NGG," where "N" can be any nucleotide.

Once the gRNA binds to the target DNA through base pairing, the Cas9 protein is recruited to the site, where it induces a double-strand break in the DNA. This break can then be repaired by the cell's natural repair mechanisms, which can lead to gene knockout, insertion, or replacement, depending on how the repair is facilitated.

Moreover, the CRISPR-Cas9 system has been optimized to improve its targeting efficiency and specificity. Various strategies have been developed to enhance the precision of gRNA design, minimize off-target effects, and improve the delivery of the CRISPR components into cells. For instance, the use of chimeric gRNAs, which combine RNA and DNA elements, has been shown to increase the specificity of the CRISPR-Cas9 system, reducing off-target cleavage while maintaining effective targeting of the intended genes [9].

In summary, the CRISPR-Cas9 system targets specific genes through the coordinated action of the Cas9 protein and a carefully designed gRNA. This system has transformed the landscape of genetic engineering, enabling precise modifications in the genomes of a wide range of organisms, from plants to animals and even humans [10][11][12].

3 Mechanism of Gene Targeting ​

3.1 gRNA Design and Target Recognition ​

The CRISPR-Cas9 system targets specific genes through a well-defined mechanism that involves the design of guide RNAs (gRNAs) and their recognition of target DNA sequences. The fundamental components of this system include the Cas9 nuclease and a gRNA, which together facilitate the precise editing of the genome.

The gRNA is designed to have a sequence complementary to the target DNA, which typically includes a protospacer-adjacent motif (PAM) that is crucial for Cas9 binding and activity. The PAM sequence, which is necessary for the recognition and cleavage of the target DNA, is usually located adjacent to the target sequence. For instance, in rice, three gRNAs were engineered to pair with distinct genomic sites, demonstrating the specificity of gRNA design, where each gRNA had a 20-22 nucleotide seed region that complemented the target site followed by the PAM [6].

Once the gRNA binds to the target DNA, the Cas9 nuclease is directed to the specific site, where it induces a double-strand break. This break can be repaired by the cell's natural repair mechanisms, which may lead to insertions or deletions (indels) at the target site. The efficiency of this process has been reported to be between 3-8% in certain studies, indicating that while the targeting is precise, the efficiency can vary based on the specific design and context [6].

The design of gRNAs is critical, as not all gRNAs are equally effective. Computational tools have been developed to predict the efficiency of gRNA sequences, aiming to select those that will maximize target specificity and minimize off-target effects. For example, recent advances have led to the development of deep learning frameworks that enhance the prediction of functional gRNAs by analyzing sequence determinants [13].

Additionally, the specificity of the Cas9 nuclease can be influenced by factors such as the position of mismatches between the gRNA and the target DNA, which has been identified as a key determinant in the targeting efficiency. Studies have shown that off-target effects, where Cas9 inadvertently cleaves non-target sites, can occur, but these effects are generally less efficient than those at perfectly matched sites [[pmid:23956122],[pmid:26575098]].

In summary, the targeting of specific genes by the CRISPR-Cas9 system is a multifaceted process that relies on the careful design of gRNAs that are complementary to the target DNA, the presence of a PAM sequence, and the optimization of the system to minimize off-target effects while maximizing on-target editing efficiency. This precise mechanism enables researchers to manipulate genetic material with high specificity, making CRISPR-Cas9 a powerful tool in genome editing.

3.2 Role of PAM (Protospacer Adjacent Motif) in Targeting ​

CRISPR-Cas9 technology utilizes a guide RNA (gRNA) to direct the Cas9 endonuclease to specific genomic locations for gene editing. A critical component of this targeting mechanism is the protospacer adjacent motif (PAM), which is an essential sequence adjacent to the target DNA sequence. The PAM is crucial for the recognition and binding of Cas9 to its target, as it allows the system to differentiate between foreign DNA and the host genome.

The PAM sequence is typically located immediately adjacent to the target sequence, and its presence is a prerequisite for Cas9 to initiate the cleavage of DNA. For instance, the commonly used Streptococcus pyogenes Cas9 (SpCas9) requires the PAM sequence 5'-NGG-3', where 'N' can be any nucleotide, but the last two nucleotides must be 'G' [14]. This requirement for a specific PAM sequence restricts the range of potential target sites for gene editing.

Research has shown that different Cas9 variants exhibit distinct PAM preferences, which can be exploited to expand the range of targetable sequences. For example, xCas9, an engineered variant of SpCas9, has been developed to recognize a broader array of PAM sequences, including NG, GAA, and GAT [14]. This broadening of PAM compatibility allows for enhanced targeting of genomic sites that would otherwise be inaccessible due to the strict PAM requirements of traditional Cas9 systems.

Additionally, the PAM plays a role in the allosteric activation of Cas9. Studies indicate that PAM binding induces conformational changes in the Cas9 protein, facilitating the cleavage of the DNA strands. The presence of the PAM sequence triggers an allosteric mechanism that activates the catalytic domains of Cas9, allowing it to perform its function of introducing double-strand breaks in the target DNA [15].

Moreover, the PAM's influence extends beyond mere binding; it is also implicated in determining the efficiency and specificity of gene editing. For instance, research has demonstrated that the PAM sequence can affect the overall cleavage activity of Cas9 variants, with some variants displaying significantly higher cleavage efficiency when paired with their optimal PAM sequences [16].

In summary, the PAM is a fundamental element in the CRISPR-Cas9 gene targeting mechanism, dictating the specificity and efficiency of the system. Its role in binding, allosteric activation, and determining the range of editable genomic sites underscores the importance of PAM in the design and application of CRISPR-based gene editing technologies.

4 Off-Target Effects and Specificity Challenges ​

4.1 Factors Contributing to Off-Target Effects ​

CRISPR-Cas9 technology is a revolutionary tool for gene editing, enabling precise modifications to specific DNA sequences. However, the specificity of CRISPR-Cas9 is challenged by off-target effects, which occur when the system inadvertently modifies unintended genomic sites. Understanding the factors that contribute to these off-target effects is crucial for improving the precision and safety of CRISPR applications.

The specificity of CRISPR-Cas9 is largely determined by the complementarity between the guide RNA (gRNA) and the target DNA sequence. Factors influencing off-target effects include the number and position of mismatches between the gRNA and the potential off-target sites. A systematic review by Modrzejewski et al. (2020) found that an increased number of mismatches significantly decreases the likelihood of off-target effects. Specifically, the rate of off-target effects decreased from 59% with one mismatch to 0% when four or more mismatches were present[17]. Additionally, mismatches located within the first eight nucleotides proximal to the protospacer adjacent motif (PAM) were found to significantly reduce off-target activity[17].

Further investigations into the sequence determinants of CRISPR-Cas9 specificity have revealed a dual-target system to measure the cleavage rates between on-target and off-target sequences. Fu et al. (2022) identified two key factors: guide-intrinsic mismatch tolerance, which is independent of the mismatch context, and an "epistasis-like" combinatorial effect of multiple mismatches, suggesting that the free-energy landscape in R-loop formation plays a critical role in determining off-target activity[18].

Moreover, Kaur Dhanjal et al. (2020) developed a machine learning-based computational model to predict off-target effects with an accuracy of 91.49%. This model considers sequence features such as accessibility, mismatches, GC-content, and position-specific conservation of nucleotides[19]. These features are essential for understanding the potential for off-target activity and improving the design of gRNAs.

Recent studies have also indicated that the stability of off-target binding is primarily influenced by the PAM-proximal seed sequences. Variations in the length of these seed sequences and the degree of mismatch tolerance can differ across different gRNAs, which highlights the complexity of predicting off-target effects[20].

Furthermore, factors such as DNA topology and the cellular context can modulate off-target activity. For instance, negative DNA supercoiling has been shown to induce genome-wide Cas9 off-target binding, suggesting that cellular processes like transcription and replication could enhance off-target effects[21].

In summary, the occurrence of off-target effects in CRISPR-Cas9 gene editing is influenced by several factors, including the number and position of mismatches in the gRNA-target sequence, the stability of the binding interactions, and the cellular environment. Understanding these factors is essential for developing strategies to minimize off-target activity, thereby enhancing the specificity and safety of CRISPR applications in therapeutic settings.

4.2 Methods to Assess and Minimize Off-Target Activity ​

CRISPR-Cas9 technology has revolutionized the field of gene editing by providing a highly efficient and precise method for targeting specific genes. However, one of the significant challenges associated with this technology is the occurrence of off-target effects, which can lead to unintended modifications in the genome. These off-target effects arise when the CRISPR guide RNA (gRNA) binds to and cleaves unintended genomic sites that are similar but not identical to the target sequence.

The specificity of the CRISPR-Cas9 system is influenced by several factors, including the design of the gRNA, the sequence of the target DNA, and the overall genomic context. A well-designed gRNA that matches the target sequence with high fidelity can minimize off-target cleavage. However, due to the inherent nature of the Cas9 nuclease, there remains a risk of binding to sequences that are only partially complementary to the gRNA. This issue is particularly pronounced in regions of the genome with high sequence similarity, where the potential for off-target activity increases.

To address these challenges, various methods have been developed to assess and minimize off-target activity. One effective strategy is the use of computational prediction algorithms that can estimate potential off-target sites based on sequence homology. These algorithms can guide researchers in selecting gRNAs with reduced off-target potential by predicting the likelihood of unintended binding events [22].

Empirical methods are also crucial for defining the off-target profile of CRISPR-Cas9. Techniques such as deep sequencing can be employed to identify off-target mutations by analyzing the entire genome following CRISPR treatment. This allows for a comprehensive assessment of off-target effects and the identification of specific unintended modifications [23]. Additionally, novel approaches such as the use of ribonucleoprotein (RNP) complexes can help minimize off-target cleavage by limiting the duration of exposure of the genome to the active editing complex [22].

Furthermore, engineering modifications to the Cas9 protein itself has shown promise in enhancing specificity. Cas9 mutants have been developed that exhibit reduced off-target cleavage compared to the wild-type enzyme, thereby improving the overall precision of gene editing applications [24]. Other strategies include the use of paired nickases, which introduce double-strand breaks at adjacent sites in the target DNA, thereby increasing the specificity of the editing process [5].

Recent advances in CRISPR technology also encompass the development of base editors and prime editing systems, which allow for more precise modifications without introducing double-strand breaks, further reducing the risk of off-target effects [25].

In summary, while CRISPR-Cas9 presents a powerful tool for gene editing, the challenge of off-target effects necessitates a multifaceted approach to enhance specificity. This includes careful gRNA design, empirical validation of off-target activity, and the application of novel engineering techniques to improve the fidelity of the CRISPR system. As research progresses, these strategies will contribute to the safe and effective application of CRISPR-Cas9 in therapeutic contexts [26][27][28].

5 Innovations and Future Directions ​

5.1 Enhanced Specificity: New Cas Variants ​

CRISPR-Cas9 technology has revolutionized gene editing by allowing precise targeting of specific genes. The mechanism relies on the ability of the Cas9 nuclease to create double-strand breaks in DNA at predetermined locations guided by RNA molecules known as guide RNAs (gRNAs). The specificity of CRISPR-Cas9 is fundamentally influenced by the design of these gRNAs, which are complementary to the target DNA sequences.

Recent advancements in CRISPR technology have led to the development of new Cas variants that enhance the specificity of gene targeting. For instance, researchers have engineered variants of Cas9, such as dCas9 (deactivated Cas9) and nCas9 (Cas9 nickase), which allow for refined editing capabilities. dCas9 can be used for gene regulation without introducing double-strand breaks, enabling the activation or silencing of target genes through fusion with transcriptional activators or repressors. This modification allows for greater control over gene expression without the risk of unwanted mutations that can occur with traditional Cas9 nuclease activity[29].

Moreover, studies have demonstrated that coupling Cas9 with artificial inhibitory domains can significantly improve target specificity. By using anti-CRISPR proteins, researchers have achieved effective kinetic insulation of on-target and off-target editing events, thus enhancing the overall precision of the CRISPR-Cas9 system[30]. This approach not only minimizes off-target effects but also broadens the range of applications for CRISPR technology in therapeutic contexts.

Another innovative strategy involves the use of base editing and prime editing techniques, which are facilitated by engineered Cas variants. Base editing allows for the direct conversion of one DNA base into another without double-strand breaks, while prime editing offers a versatile platform for making precise edits with reduced off-target risks[31]. These advanced methods have been applied successfully to improve agronomic traits in crops, demonstrating the potential of CRISPR-Cas systems beyond traditional gene editing applications[29].

In summary, the enhanced specificity of CRISPR-Cas9 targeting specific genes is achieved through the engineering of novel Cas variants, the use of advanced editing techniques, and innovative strategies that minimize off-target effects. These developments not only enhance the precision of gene editing but also expand the therapeutic potential of CRISPR technology, paving the way for more effective treatments for genetic disorders and improved agricultural practices[32][33][34].

5.2 Applications in Gene Therapy and Beyond ​

CRISPR-Cas9 technology represents a significant advancement in gene editing, enabling precise modifications of DNA within living organisms. The mechanism by which CRISPR-Cas9 targets specific genes is primarily based on the use of RNA-guided nucleases, specifically the Cas9 protein, which is directed to specific genomic locations by short RNA sequences known as guide RNAs (gRNAs). This system, derived from the adaptive immune responses of bacteria, allows for targeted genome editing through the formation of double-strand breaks at predetermined sites in the DNA.

The targeting process begins with the design of a gRNA that is complementary to a specific DNA sequence in the target gene. When the gRNA is introduced into a cell along with the Cas9 protein, the gRNA binds to its target DNA sequence through base pairing. This binding facilitates the recruitment of the Cas9 nuclease, which then induces a double-strand break in the DNA at the targeted location. The cell's natural repair mechanisms subsequently attempt to fix this break, which can lead to either the insertion of new genetic material or the disruption of the target gene, depending on the repair pathway that is activated [34].

Innovations in CRISPR-Cas9 technology have focused on enhancing its specificity and efficiency to minimize off-target effects, which are unintended modifications at non-target sites. Advances include the development of engineered nucleases, improved gRNA design, and novel Cas9 orthologs that exhibit enhanced targeting capabilities [35]. Additionally, methods to detect and characterize off-target effects are continuously being refined, allowing researchers to better predict and mitigate these occurrences [33].

The applications of CRISPR-Cas9 extend beyond basic research into therapeutic contexts, particularly in gene therapy. The ability to precisely edit genes has made CRISPR-Cas9 a promising tool for treating genetic disorders by correcting disease-causing mutations at their source. For instance, inherited hematological disorders are considered ideal candidates for CRISPR-Cas9-mediated gene therapy, as the technology can potentially alleviate disease symptoms by correcting specific mutations [36]. Furthermore, CRISPR-Cas9 has shown promise in oncology, where it can be used to edit cancer-driving mutations, enhance immune responses against tumors, and develop novel cancer therapies [37].

Looking ahead, the future directions for CRISPR-Cas9 technology in gene therapy include the exploration of improved delivery systems, such as lipid nanoparticles and exosomes, which can enhance the safety and efficacy of CRISPR-based therapies [38]. The regulatory landscape is also evolving to support these innovations, with frameworks in place to expedite the approval of gene therapies [37]. However, ethical considerations surrounding the use of CRISPR-Cas9, particularly in germline editing and potential off-target effects, remain critical issues that necessitate ongoing scrutiny and oversight [34].

In summary, CRISPR-Cas9 targets specific genes through a highly precise mechanism involving RNA-guided nucleases, with ongoing innovations aimed at enhancing its specificity and therapeutic applications. The potential of this technology to revolutionize gene therapy and address a wide range of genetic disorders is significant, marking a new era in precision medicine.

6 Ethical Considerations in CRISPR Applications ​

6.1 Ethical Implications of Gene Editing in Humans ​

The knowledge base information is insufficient. Please consider switching to a different knowledge base or supplementing relevant literature.

6.2 Regulatory Framework and Public Perception ​

CRISPR-Cas9 technology targets specific genes through a mechanism that involves a guide RNA (gRNA) which directs the Cas9 nuclease to a specific sequence in the genome. The guide RNA is designed to be complementary to the target DNA sequence, allowing the Cas9 enzyme to recognize and bind to this specific site. Once bound, Cas9 introduces a double-strand break in the DNA, which can then be repaired by the cell's natural repair mechanisms, either through non-homologous end joining or homology-directed repair, allowing for gene modification or knockout (Liu et al., 2017; Ghosh et al., 2019).

Despite the powerful capabilities of CRISPR-Cas9, ethical considerations are paramount, especially in therapeutic applications. The potential for off-target effects, where unintended parts of the genome are modified, raises significant concerns about the safety and long-term consequences of using this technology in humans. There is also the ethical dilemma surrounding germline editing, which could have implications for future generations. The necessity for rigorous oversight and ethical frameworks is critical to guide the responsible use of CRISPR technology in clinical settings (Khadempar et al., 2019; Bhat et al., 2022).

Regulatory frameworks surrounding CRISPR applications vary significantly across different countries. In the United States, the FDA oversees gene therapies, including those utilizing CRISPR, ensuring that they meet safety and efficacy standards before reaching clinical trials. Conversely, some countries have more stringent regulations or outright bans on germline editing. Public perception of CRISPR technology is influenced by its portrayal in the media, scientific discourse, and public engagement efforts. Misunderstandings or fears about genetic modification can lead to public resistance, making it essential for scientists and policymakers to engage with the community to foster understanding and acceptance of the technology (de Buhr & Lebbink, 2018; Nasrallah et al., 2022).

In summary, while CRISPR-Cas9 provides a revolutionary tool for precise gene targeting, the associated ethical considerations, regulatory frameworks, and public perception must be carefully navigated to ensure its responsible application in medicine and biotechnology.

7 Conclusion ​

The CRISPR-Cas9 system has emerged as a pivotal technology in genetic engineering, offering unprecedented precision in gene targeting and modification. The primary findings from the review highlight the intricate mechanisms underlying CRISPR-Cas9 functionality, including the essential roles of guide RNA (gRNA) design and the protospacer adjacent motif (PAM) in ensuring specificity. Despite its transformative potential, the challenge of off-target effects remains a significant concern, necessitating ongoing research to enhance the system's accuracy and safety. Current innovations, such as the development of new Cas variants and advanced editing techniques like base editing and prime editing, are promising avenues for improving the precision of CRISPR applications. Future research directions should focus on refining gRNA design, optimizing delivery methods, and addressing ethical implications surrounding gene editing, particularly in human applications. The responsible advancement of CRISPR-Cas9 technology holds the potential to revolutionize fields such as gene therapy and agriculture, making it imperative to balance innovation with ethical considerations and public engagement.

References ​

  • [1] Yeliz Demirci;Baohong Zhang;Turgay Unver. CRISPR/Cas9: An RNA-guided highly precise synthetic tool for plant genome editing.. Journal of cellular physiology(IF=4.0). 2018. PMID:28430356. DOI: 10.1002/jcp.25970.
  • [2] Nivya Kolli;Ming Lu;Panchanan Maiti;Julien Rossignol;Gary L Dunbar. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.. Neurochemistry international(IF=4.0). 2018. PMID:28732771. DOI: 10.1016/j.neuint.2017.07.007.
  • [3] Diana Raquel Rodríguez-Rodríguez;Ramiro Ramírez-Solís;Mario Alberto Garza-Elizondo;María De Lourdes Garza-Rodríguez;Hugo Alberto Barrera-Saldaña. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review).. International journal of molecular medicine(IF=5.8). 2019. PMID:30816503. DOI: 10.3892/ijmm.2019.4112.
  • [4] Debarati Ghosh;Prabhadevi Venkataramani;Saikat Nandi;Sonali Bhattacharjee. CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics.. Cancer cell international(IF=6.0). 2019. PMID:30636933. DOI: 10.1186/s12935-019-0726-0.
  • [5] Saedeh Khadempar;Shokoufeh Familghadakchi;Roozbeh Akbari Motlagh;Najmeh Farahani;Maryam Dashtiahangar;Hamzeh Rezaei;Seyed Mohammad Gheibi Hayat. CRISPR-Cas9 in genome editing: Its function and medical applications.. Journal of cellular physiology(IF=4.0). 2019. PMID:30362544. DOI: 10.1002/jcp.27476.
  • [6] Kabin Xie;Yinong Yang. RNA-guided genome editing in plants using a CRISPR-Cas system.. Molecular plant(IF=24.1). 2013. PMID:23956122. DOI: 10.1093/mp/sst119.
  • [7] Ali Nasrallah;Eric Sulpice;Farah Kobaisi;Xavier Gidrol;Walid Rachidi. CRISPR-Cas9 Technology for the Creation of Biological Avatars Capable of Modeling and Treating Pathologies: From Discovery to the Latest Improvements.. Cells(IF=5.2). 2022. PMID:36429042. DOI: 10.3390/cells11223615.
  • [8] Saeed Kaboli;Hasan Babazada. CRISPR Mediated Genome Engineering and its Application in Industry.. Current issues in molecular biology(IF=3.0). 2018. PMID:28879858. DOI: 10.21775/cimb.026.081.
  • [9] Hanseop Kim;Wi-Jae Lee;Yeounsun Oh;Seung-Hun Kang;Junho K Hur;Hyomin Lee;WooJeung Song;Kyung-Seob Lim;Young-Ho Park;Bong-Seok Song;Yeung Bae Jin;Bong-Hyun Jun;Cheulhee Jung;Dong-Seok Lee;Sun-Uk Kim;Seung Hwan Lee. Enhancement of target specificity of CRISPR-Cas12a by using a chimeric DNA-RNA guide.. Nucleic acids research(IF=13.1). 2020. PMID:32687187. DOI: 10.1093/nar/gkaa605.
  • [10] Yuduan Ding;Hong Li;Ling-Ling Chen;Kabin Xie. Recent Advances in Genome Editing Using CRISPR/Cas9.. Frontiers in plant science(IF=4.8). 2016. PMID:27252719. DOI: 10.3389/fpls.2016.00703.
  • [11] Chang Liu;Li Zhang;Hao Liu;Kun Cheng. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.. Journal of controlled release : official journal of the Controlled Release Society(IF=11.5). 2017. PMID:28911805. DOI: 10.1016/j.jconrel.2017.09.012.
  • [12] Rongfang Xu;Hao Li;Ruiying Qin;Lu Wang;Li Li;Pengcheng Wei;Jianbo Yang. Gene targeting using the Agrobacterium tumefaciens-mediated CRISPR-Cas system in rice.. Rice (New York, N.Y.)(IF=5.0). 2014. PMID:24920971. DOI: 10.1186/s12284-014-0005-6.
  • [13] Li Xue;Bin Tang;Wei Chen;Jiesi Luo. Prediction of CRISPR sgRNA Activity Using a Deep Convolutional Neural Network.. Journal of chemical information and modeling(IF=5.3). 2019. PMID:30485088. DOI: 10.1021/acs.jcim.8b00368.
  • [14] Johnny H Hu;Shannon M Miller;Maarten H Geurts;Weixin Tang;Liwei Chen;Ning Sun;Christina M Zeina;Xue Gao;Holly A Rees;Zhi Lin;David R Liu. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.. Nature(IF=48.5). 2018. PMID:29512652. DOI: 10.1038/nature26155.
  • [15] Giulia Palermo;Clarisse G Ricci;Amendra Fernando;Rajshekhar Basak;Martin Jinek;Ivan Rivalta;Victor S Batista;J Andrew McCammon. Protospacer Adjacent Motif-Induced Allostery Activates CRISPR-Cas9.. Journal of the American Chemical Society(IF=15.6). 2017. PMID:28764328. DOI: 10.1021/jacs.7b05313.
  • [16] Haihua Xie;Lianchao Tang;Xiubin He;Xiexie Liu;Chenchen Zhou;Junjie Liu;Xianglian Ge;Jin Li;Changbao Liu;Junzhao Zhao;Jia Qu;Zongming Song;Feng Gu. SaCas9 Requires 5'-NNGRRT-3' PAM for Sufficient Cleavage and Possesses Higher Cleavage Activity than SpCas9 or FnCpf1 in Human Cells.. Biotechnology journal(IF=3.1). 2018. PMID:29247600. DOI: 10.1002/biot.201700561.
  • [17] Dominik Modrzejewski;Frank Hartung;Heike Lehnert;Thorben Sprink;Christian Kohl;Jens Keilwagen;Ralf Wilhelm. Which Factors Affect the Occurrence of Off-Target Effects Caused by the Use of CRISPR/Cas: A Systematic Review in Plants.. Frontiers in plant science(IF=4.8). 2020. PMID:33329634. DOI: 10.3389/fpls.2020.574959.
  • [18] Rongjie Fu;Wei He;Jinzhuang Dou;Oscar D Villarreal;Ella Bedford;Helen Wang;Connie Hou;Liang Zhang;Yalong Wang;Dacheng Ma;Yiwen Chen;Xue Gao;Martin Depken;Han Xu. Systematic decomposition of sequence determinants governing CRISPR/Cas9 specificity.. Nature communications(IF=15.7). 2022. PMID:35078987. DOI: 10.1038/s41467-022-28028-x.
  • [19] Jaspreet Kaur Dhanjal;Samvit Dammalapati;Shreya Pal;Durai Sundar. Evaluation of off-targets predicted by sgRNA design tools.. Genomics(IF=3.0). 2020. PMID:32353475. DOI: 10.1016/j.ygeno.2020.04.024.
  • [20] Neha Rohatgi;Jean-Philippe Fortin;Ted Lau;Yi Ying;Yue Zhang;Bettina L Lee;Michael R Costa;Rohit Reja. Seed sequences mediate off-target activity in the CRISPR-interference system.. Cell genomics(IF=9.0). 2024. PMID:39510079. DOI: 10.1016/j.xgen.2024.100693.
  • [21] Matthew D Newton;Marialucrezia Losito;Quentin M Smith;Nishita Parnandi;Benjamin J Taylor;Pinar Akcakaya;Marcello Maresca;Patrick van Eijk;Simon H Reed;Simon J Boulton;Graeme A King;Maria Emanuela Cuomo;David S Rueda. Negative DNA supercoiling induces genome-wide Cas9 off-target activity.. Molecular cell(IF=16.6). 2023. PMID:37802026. DOI: 10.1016/j.molcel.2023.09.008.
  • [22] Christopher A Vakulskas;Mark A Behlke. Evaluation and Reduction of CRISPR Off-Target Cleavage Events.. Nucleic acid therapeutics(IF=4.7). 2019. PMID:31107154. DOI: 10.1089/nat.2019.0790.
  • [23] Jeffrey D Wolt;Kan Wang;Dipali Sashital;Carolyn J Lawrence-Dill. Achieving Plant CRISPR Targeting that Limits Off-Target Effects.. The plant genome(IF=3.8). 2016. PMID:27902801. DOI: 10.3835/plantgenome2016.05.0047.
  • [24] John Paul Shen;Trey Ideker. Correcting CRISPR for copy number.. Nature genetics(IF=29.0). 2017. PMID:29186130. DOI: 10.1038/ng.3994.
  • [25] Muhammad Naeem;Saman Majeed;Mubasher Zahir Hoque;Irshad Ahmad. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.. Cells(IF=5.2). 2020. PMID:32630835. DOI: 10.3390/cells9071608.
  • [26] Zeinab Sherkatghanad;Moloud Abdar;Jeremy Charlier;Vladimir Makarenkov. Using traditional machine learning and deep learning methods for on- and off-target prediction in CRISPR/Cas9: a review.. Briefings in bioinformatics(IF=7.7). 2023. PMID:37080758. DOI: 10.1093/bib/bbad131.
  • [27] Guillermo Aquino-Jarquin. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.. Molecular genetics and metabolism(IF=3.5). 2021. PMID:34391646. DOI: 10.1016/j.ymgme.2021.08.002.
  • [28] Josh Tycko;Vic E Myer;Patrick D Hsu. Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.. Molecular cell(IF=16.6). 2016. PMID:27494557. DOI: .
  • [29] Ranjit Singh Gujjar;Shehla Sherin;Sejal Batra;Arunima Mahto;Sanjay Kumar Goswami;Rajeev Kumar;Rahul Kumar Tiwari;Arjun Singh;Mala Kumari. Emerging trends in the development of efficient CAS nucleases for meticulous gene editing in plants.. Plant science : an international journal of experimental plant biology(IF=4.1). 2026. PMID:41109509. DOI: 10.1016/j.plantsci.2025.112820.
  • [30] Sabine Aschenbrenner;Stefan M Kallenberger;Mareike D Hoffmann;Adrian Huck;Roland Eils;Dominik Niopek. Coupling Cas9 to artificial inhibitory domains enhances CRISPR-Cas9 target specificity.. Science advances(IF=12.5). 2020. PMID:32076642. DOI: 10.1126/sciadv.aay0187.
  • [31] Eric Deneault. Recent Therapeutic Gene Editing Applications to Genetic Disorders.. Current issues in molecular biology(IF=3.0). 2024. PMID:38785523. DOI: 10.3390/cimb46050255.
  • [32] Julia Marsiglia;Kia Vaalavirta;Estefany Knight;Muneaki Nakamura;Le Cong;Nicholas W Hughes. Computationally guided high-throughput engineering of an anti-CRISPR protein for precise genome editing in human cells.. Cell reports methods(IF=4.5). 2024. PMID:39437714. DOI: 10.1016/j.crmeth.2024.100882.
  • [33] Xiaoqiang Huang;Dongshan Yang;Jifeng Zhang;Jie Xu;Y Eugene Chen. Recent Advances in Improving Gene-Editing Specificity through CRISPR-Cas9 Nuclease Engineering.. Cells(IF=5.2). 2022. PMID:35883629. DOI: 10.3390/cells11142186.
  • [34] Zuber Khan; Mumtaz;Sumedha Gupta;Sidharth Mehan;Tarun Sharma;Manjeet Kumar;Pankaj Kumar Maurya;Arun Kumar Sharma;Ghanshyam Das Gupta;Acharan S Narula. CRISPR-Cas9: Transforming Functional Genomics, Precision Medicine, and Drug Development - Opportunities, Challenges, and Future Directions.. Current gene therapy(IF=3.3). 2025. PMID:40129147. DOI: 10.2174/0115665232376648250312050239.
  • [35] Muhammad Jamal;Arif Ullah;Muhammad Ahsan;Rohit Tyagi;Zeshan Habib;Khaista Rehman. Improving CRISPR-Cas9 On-Target Specificity.. Current issues in molecular biology(IF=3.0). 2018. PMID:28879857. DOI: 10.21775/cimb.026.065.
  • [36] Han Zhang;Nami McCarty. CRISPR-Cas9 technology and its application in haematological disorders.. British journal of haematology(IF=3.8). 2016. PMID:27619566. DOI: 10.1111/bjh.14297.
  • [37] Emile Youssef;Brandon Fletcher;Dannelle Palmer. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology.. Frontiers in medicine(IF=3.0). 2024. PMID:39871848. DOI: 10.3389/fmed.2024.1527600.
  • [38] Kuldeep Singh;Bharat Bhushan;Sunil Kumar;Supriya Singh;Romulo R Macadangdang;Ekta Pandey;Ajit Kumar Varma;Shivendra Kumar. Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects.. Current gene therapy(IF=3.3). 2024. PMID:38258771. DOI: 10.2174/0115665232279528240115075352.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

CRISPR-Cas9 · gene editing · targeted genes · guide RNA · off-target effects

© 2025 MaltSci